- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Pelthos rolls out Zelsuvmi with campaign aimed at moms who 'don't mess around' | 3 | FiercePharma | ||
| Do | Pelthos launches Moms Against Molluscum campaign for skin infection | 1 | Investing.com | ||
| Do | Pelthos startet Kampagne "Moms Against Molluscum" für neues Hautinfektionsmittel | 1 | Investing.com Deutsch | ||
| 03.09. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Oppenheimer initiates Pelthos Therapeutics stock with Outperform rating | 3 | Investing.com | ||
| PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.08. | Ligand Q1 2025: Umsatz steigt um 46 %, strategische Fusion zu Pelthos angekündigt | 1 | Investing.com Deutsch | ||
| 20.08. | Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced | 2 | Investing.com | ||
| 18.08. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.08. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update | 518 | GlobeNewswire (Europe) | Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI... ► Artikel lesen | |
| 13.08. | Pelthos Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 25.07. | Pelthos Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.07. | Ligand Pharma Earns Milestone Payment From Pelthos On Commercial Launch Of ZELSUVMI | 394 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals (LGND) announced that its partner Pelthos Therapeutics Inc. (PTHS) has commercially launched ZELSUVMI or berdazimer topical gel 10.3%, the first... ► Artikel lesen | |
| 10.07. | Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease | 1 | Benzinga.com | ||
| 10.07. | Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI | 263 | GlobeNewswire (Europe) | JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially... ► Artikel lesen | |
| 02.07. | Pelthos Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Ligand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In July | 445 | AFX News | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics... ► Artikel lesen | |
| 02.07. | Ligand schließt Fusion ab, Pelthos bringt Molluscum-Behandlung auf den Markt | 6 | Investing.com Deutsch | ||
| 02.07. | Ligand completes merger, Pelthos to launch molluscum treatment | 2 | Investing.com | ||
| 02.07. | Ligand Pharmaceuticals: Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics | 222 | GlobeNewswire (Europe) | Pelthos plans to launch ZELSUVMI for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company... ► Artikel lesen | |
| 27.06. | Channel Therapeutics announces 10-for-1 reverse split ahead of NYSE American uplisting | 2 | Seeking Alpha |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,786 | +1,31 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| VALNEVA | 4,482 | +0,18 % | Valneva korrigiert Finanzziele - Hoffnung bleibt auf Lyme-Impfstoff ab 2027 | Valneva hat eine neue Kreditfazilität über bis zu 500 Millionen US-Dollar mit von Pharmakon Advisors verwalteten Fonds abgeschlossen. Eine erste Tranche von 215 Millionen US-Dollar dient zur vollständigen... ► Artikel lesen | |
| MAINZ BIOMED | 1,555 | -3,42 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed berichtet Topline-Ergebnisse aus der Machbarkeitsstudie zum Biomarker-Panel im Rahmen seines Bauchspeicheldrüsenkrebs-Projekts | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studienergebnisse
Mainz Biomed berichtet Topline-Ergebnisse aus der Machbarkeitsstudie zum Biomarker-Panel im Rahmen... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,960 | -1,57 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 | SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| ADMA BIOLOGICS | 14,550 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| NUVALENT | 89,75 | +1,79 % | Nuvalent präsentiert neue Daten zu HER2-Inhibitor auf Krebskonferenz | ||
| TARSUS PHARMACEUTICALS | 70,34 | +0,31 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| ARCELLX | 86,23 | -0,65 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| QIAGEN | 40,955 | +1,20 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,720 | +3,34 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,390 | -3,61 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| COGENT BIOSCIENCES | 16,200 | -0,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| CG ONCOLOGY | 42,960 | -0,72 % | Why Cg Oncology Stock Rocketed 7% Higher Today | ||
| LENZ THERAPEUTICS | 38,610 | -0,34 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| MINERALYS THERAPEUTICS | 43,050 | +9,29 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD |
Das Unternehmen PELTHOS THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 24,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PELTHOS THERAPEUTICS INC finden Sie auf Wallstreet Online.